Medically reviewed by Dr. Ploy, MD, Qualified Peptide Therapy Doctor, Board Certified in Family Medicine, Regenerative & Longevity Medicine Specialist , licensed by the Medical Council of Thailand.
Last reviewed: June 2026
Retatrutide’s trial numbers have generated more interest than any metabolic compound in recent memory. The TRIUMPH 4 phase 3 trial reported a 28.7 percent average body weight loss at 68 weeks. Separate published data shows dramatic reductions in liver fat and significant improvements in insulin sensitivity. The mechanism, which simultaneously targets GLP-1, GIP and glucagon receptors, is genuinely new.
But the side effects that receive the least attention online are the ones that matter most to anyone considering it: significant lean muscle loss documented by DEXA scanning, dopamine suppression that can flatten mood and drive, and dosing decisions where the difference between 8 mg and 12 mg is roughly 1 percent more fat loss and approximately double the side effects. This article covers what the studies actually show across all of these, and why physician supervision is not a formality.
If you are new to retatrutide, start with what retatrutide is and its availability in Thailand first, or the mechanism deep-dive on retatrutide for the triple receptor science. This article builds on that foundation.
What the TRIUMPH 4 Phase 3 Data Actually Shows
The phase 2 data that first made headlines reported approximately 24 percent body weight loss at 48 weeks. The phase 3 TRIUMPH program has now published its first results. Eli Lilly’s December 2025 press release reported average weight loss of up to 71.2 lbs at the highest dose, alongside substantial relief from osteoarthritis pain. The headline figures by dose group:
| Dose group | Average body weight loss |
|---|---|
| 12 mg/week | 28.7% (up to 71.2 lbs average) |
| 9 mg/week | 26.4% |
For context, semaglutide’s STEP 1 phase 3 trial reported approximately 14.9 percent average weight loss. Tirzepatide’s SURMOUNT-1 reported up to 22.5 percent. Retatrutide at 12 mg exceeds both by a meaningful margin. The 71.2 lbs figure is the trial average at that dose, not the best-case result.
That is the headline. What sits beneath it is where the clinical picture becomes more complex.
The Benefits Beyond Weight Loss
Weight loss is the most searched outcome, but the published trial data extends considerably further.
Fatty Liver Reversal
Non-alcoholic fatty liver disease affects roughly one in four adults, often with no symptoms until significant damage has already occurred. A 2024 phase 2 trial published in Nature Medicine enrolled 98 adults with confirmed obesity and fatty liver, treating them with retatrutide once weekly for 48 weeks. Results by dose group:
| Dose | Reduction in liver fat |
|---|---|
| 4 mg | 57% |
| 8 mg | 81% |
| 12 mg | 82% |
Two things stand out. First, even at the moderate 4 mg dose, liver fat dropped by more than half. Second, the jump from 8 mg to 12 mg produced only 1 percent additional benefit. This pattern repeats across multiple outcome measures and has direct implications for how a responsible dosing protocol should be structured.
Fatty liver is a key driver of cardiovascular risk, insulin resistance and metabolic dysfunction. Reversal at this scale is clinically significant and is not a side effect of the weight loss alone. The glucagon receptor mechanism appears to drive direct hepatic fat mobilisation independently of caloric restriction.
Insulin Resistance
Insulin resistance affects approximately one in three adults and is frequently invisible for years. Blood glucose can remain normal while insulin rises steadily to compensate, until the system finally fails and type 2 diabetes or metabolic syndrome emerges. A phase 2 trial published in The Lancet gave retatrutide at doses between 4 mg and 12 mg once weekly to patients with confirmed insulin resistance. Within 36 weeks, 82 percent reached healthy blood sugar levels.
If you want to assess your own metabolic baseline before any protocol, the key markers are: fasting insulin and fasting glucose (calculate HOMA-IR: glucose multiplied by insulin divided by 405, target below 2), high-sensitivity CRP (below 1), ferritin (50 to 100), free T3, and the triglyceride-to-HDL ratio (below 2). A physician reviewing these before starting gives you a reference point and determines whether intervention is warranted.
Osteoarthritis Pain Relief
The December 2025 phase 3 data reported a finding that has received little coverage relative to the weight loss headline: substantial relief from osteoarthritis pain. This is significant for two reasons.
First, osteoarthritis is one of the most common chronic pain conditions globally and is directly worsened by excess body weight. The mechanical load on joints compounds the inflammatory damage, and most treatments manage symptoms rather than addressing the underlying drivers. Weight loss at the scale retatrutide achieves reduces that mechanical load considerably.
Second, the glucagon receptor component of retatrutide’s mechanism appears to have direct anti-inflammatory effects beyond what weight loss alone produces. This suggests the pain relief observed in the trial is not purely a downstream consequence of losing weight but may involve a separate pathway. The research here is still maturing, but it is a clinically meaningful finding for anyone whose obesity has been accompanied by joint deterioration.
If osteoarthritis is relevant to your situation, this should be part of the conversation with your physician before starting any protocol.
Start with a full metabolic assessment.
Your physician reviews your baseline labs before recommending any protocol. No guesswork, no generic dosing schedules.
The Four Costs Almost Nobody Discusses
Every review of retatrutide leads with the weight loss result. Very few discuss what it costs. The following are documented in published clinical data and are not edge cases.
Cost One: Significant Lean Muscle Loss
In the phase 2 trials, researchers ran DEXA scans on participants throughout the weight loss period to determine what type of tissue was actually disappearing. The result: approximately 26 percent of total weight lost was lean muscle rather than fat. On a typical protocol where someone loses 40 to 50 lbs, that means 10 to 13 lbs of muscle lost alongside the fat.
The mechanism is the ubiquitin-proteasome pathway. When GLP-1 receptors are activated at the scale that retatrutide achieves, the body interprets sustained caloric restriction as a famine state. The nervous system responds by breaking down muscle tissue for energy. This is not a malfunction. It is biology doing exactly what it is designed to do under perceived starvation conditions.
The critical nuance here: protein intake alone does not prevent this. Protein provides raw materials for muscle protein synthesis, but it does not switch off the catabolic pathway driving the breakdown. A physician-supervised protocol that takes muscle preservation seriously addresses it through three non-negotiable pillars:
- Protein: approximately 1 g per pound of lean body mass daily, maintained consistently even when appetite is significantly suppressed
- Branched-chain amino acids: leucine in particular directly suppresses catabolism signalling at the source rather than just providing substrate; this addresses the pathway protein alone cannot
- Resistance training: a minimum of three sessions per week, maintained throughout the protocol; strength training sends the physiological signal to retain muscle that caloric restriction removes
These are not optional additions to the protocol. Without them, the DEXA data suggests muscle loss at the scale above is likely. A physician structuring your protocol will set targets across all three before the first dose.
Cost Two: Anhedonia and Dopamine Suppression
This side effect is underreported partly because it is subtle and partly because it does not appear in standard labs. Anhedonia is the clinical term for a reduced ability to experience pleasure or reward. Retatrutide, like other drugs in the GLP-1 class, crosses the blood-brain barrier and influences dopamine signalling in the nucleus accumbens, the brain’s primary reward centre.
The practical experience varies. For some it manifests as food simply becoming less interesting, which some people actively want. For others, particularly those whose reward system is more broadly engaged through food, social interaction or creative work, the flattening extends into mood, drive and libido. It tends to be dose-dependent and is more prominent during aggressive titration.
There is no pharmacological fix that restores dopamine while the drug is active. What can be addressed is the nutritional substrate problem that makes anhedonia worse. The foundations that support dopamine precursor synthesis include:
- Vitamin D maintained at approximately 50 ng/mL
- Magnesium glycinate 400 mg before bed
- Methylated B complex daily
These support the raw materials the central nervous system uses to produce neurotransmitters. They do not replace what the drug suppresses, but they prevent nutrient deficiency from compounding the effect. A physician discussing whether retatrutide is appropriate for you will take your baseline mood and motivation into account before recommending it.
Cost Three: What Happens When You Stop
Retatrutide’s discontinuation profile appears more favourable than that of single-agonist GLP-1 drugs, where near-complete weight regain within 18 months is well documented in the literature. Some researchers have reported significantly lower post-discontinuation rebound for retatrutide, attributed in part to the glucagon mechanism producing more durable changes to hepatic fat metabolism and insulin sensitivity.
However, the data on this is not yet conclusive; this is an area where the research is still maturing. What is established across the class is that when the drug stops, hunger returns, metabolic rate may decline, insulin sensitivity may worsen and fat oxidation drops. Whether the rebound is modest or near-complete for retatrutide specifically is not yet answered with certainty.
The implication for anyone considering it: the drug provides a window, a metabolic reset that most people cannot achieve through lifestyle alone. Whether that window translates into lasting change depends almost entirely on what is built during it. A physician-supervised protocol does not end at the last injection. It includes a structured transition plan and a maintenance framework designed to hold what the window created.
Cost Four: Dosing Traps
The TRIUMPH 4 data makes a specific and clinically important point. The difference in fat loss between the 8 mg and 12 mg weekly dose groups was approximately 1 percent. Side effects at the 12 mg level roughly doubled. The Nature Medicine fatty liver trial made the same point: 8 mg achieved 81 percent liver fat reduction, 12 mg achieved 82 percent.
This is the dosing trap. Most people researching retatrutide online see the 12 mg number from the phase 3 trial and assume that is the target. They titrate fast because they want results fast. The pharmacology does not work that way. Aggressive titration does not accelerate fat loss by 300 percent. It increases side effects by that margin while delivering approximately 1 percent more outcome than a sensible mid-range dose.
The responsible clinical approach is to titrate slowly, evaluate response at each stage with monitoring, and stop increasing when results are adequate rather than when the theoretical maximum has been reached. This is the kind of decision that requires a physician seeing your labs and your response over time, not a fixed schedule from a forum.
Physician supervision is what changes the outcome.
Every protocol includes medical oversight, clinical-grade sourcing and a physician who reviews your labs, not just your goals.
Why Physician Supervision Is Not Optional With Retatrutide
Each of the four costs above is manageable within a well-structured physician-supervised protocol. None of them can be meaningfully monitored through self-dosing.
Muscle loss requires individual protein and training targets, assessed against actual lean mass rather than a generic guideline. Anhedonia requires a baseline assessment and nutritional foundation established before the first dose. Discontinuation requires a structured plan that begins before the last injection, not after rebound weight gain has already started. Dosing requires labs and clinical judgment at each titration point, not a Reddit thread.
Retatrutide carries an additional layer of complexity: it is still an investigational compound. It has not completed its full regulatory review anywhere in the world. Pairing an unverified research-grade product with an incomplete safety profile and no medical monitoring is genuinely one of the riskier decisions a person can make in this category. At Peptides Thailand, retatrutide is offered only under physician supervision with clinical-grade, verifiable sourcing and Certificates of Analysis on every batch. If retatrutide is not the right fit for your situation, approved options including semaglutide and tirzepatide are available through the same framework.
The Right Starting Point
The trial data is compelling. The window retatrutide provides is real. But the window is only useful if what you are keeping (muscle mass, metabolic baseline, mood) is protected while you are using it.
The right starting point is a physician who can review your labs, discuss your goals honestly, structure a protocol around the documented costs above and guide you through the discontinuation phase when it arrives.
Book a consultation with Peptides Thailand to start that conversation.
